Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia

Immunology and Cell Biology

Volumn 89, Issue 3, 2011, Pages 396-407

  Bleakley, Marie ^a   Riddell, Stanley R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

adoptive T cell transfer; antigen discovery; immunotherapy; leukemia; minor histocompatibility antigens; T cells

Indexed keywords

BCL2 RELATED PROTEIN A1; CD19 ANTIGEN; EXCITATORY AMINO ACID TRANSPORTER 1; GLUCURONOSYLTRANSFERASE 2B7; LIVER RECEPTOR HOMOLOG 1; MINOR HISTOCOMPATIBILITY ANTIGEN; PURINERGIC P2X5 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL LINEAGE; DNA LIBRARY; DONOR LYMPHOCYTE INFUSION; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOGENICITY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LYMPHOBLASTOID CELL LINE; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; NONSENSE MUTATION; OUTCOME ASSESSMENT; PROTEIN TRANSPORT; REVIEW; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VACCINATION;

EID: 79952815781     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.124     Document Type: Review

References (155)

1. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. BMJ 1956; 2: 626-627.
2. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-1073. (Pubitemid 9198740)
3. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrowtransplantation. N Engl J Med 1981; 304: 1529-1533. (Pubitemid 11065939)
4. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influenceof acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728. (Pubitemid 19133213)
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562. (Pubitemid 20069191)
6. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389. (Pubitemid 32467049)
7. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371-380. (Pubitemid 38579483)
8. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effec-tiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)
9. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haemato-poietictransplants. Nat Rev Immunol 2003; 3: 108-122. (Pubitemid 37328689)
10. Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 84-90. (Pubitemid 350192306)
11. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21: 525-530.
12. Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneictransplantation: effect on engraftment, graft-versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant 2009; 15: 765-776.
13. Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009; 361: 478-488.
14. Ryan M, Diekhans M, Lien S, Liu Y, Karchin R. LS-SNP/PDB: annotated non-synonymous SNPs mapped to Protein Data Bank structures. Bioinformatics 2009; 25: 1431-1432.
15. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression duetoa genedeletion. J Exp Med 2003; 197: 1279-1289. (Pubitemid 36617774)
16. Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y et al. Hap Map scanning of novel human minor histocompatibility antigens. Blood 2009; 113: 5041-5048.
17. Terakura S, Murata M, Warren EH, Sette A, Sidney J, Naoe T et al. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and-B*4403. Transplantation 2007; 83: 1242-1248. (Pubitemid 46743687)
18. McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet 2009; 41: 1341-1344.
19. Brickner AG, Evans AM, Mito JK, Xuereb SM, Feng X, Nishida T et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectivelyexpressed in B-lymphoid cellsand B-CLL. Blood 2006; 107: 3779-3786.
20. Brickner AG, Warren EH, Caldwell JA, Akatsuka Y, Golovina TN, Zarling AL et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001; 193: 195-206.
21. Spierings E, Brickner AG, Caldwell JA, Zegveld S, Tatsis N, Blokland E et al. Theminor histocompatibility antigen HA-3 arises from differential proteasome-mediated clea-vage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 2003; 102: 621-629. (Pubitemid 36841984)
22. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al. The minor histocompatibility antigen HA-1: a diallelic genewith a single amino acid polymorph-ism. Science 1998; 279: 1054-1057. (Pubitemid 28113311)
23. Nicholls S, Piper KP, Mohammed F, Dafforn TR, Tenzer S, Salim M et al. Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen criticallyaffects MHC stability and TCR recognition. Proc Natl Acad Sci USA2009; 106: 3889-3894.
24. Spierings E, Gras S, Reiser JB, Mommaas B, Almekinders M, Kester MG et al. Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele. J Immunol 2009; 182: 4809-4816.
25. Torikai H, Akatsuka Y, Miyazaki M, Tsujimura A, Yatabe Y, Kawase T et al. The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and-A*3303. Br J Haematol 2006; 134: 406-416. (Pubitemid 44079554)
26. Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006; 107: 4954-4960. (Pubitemid 43882650)
27. van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007; 109: 4089-4096. (Pubitemid 46641765)
28. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW et al. Identification of a graft versus host disease-associated human minor histocompat-ibilityantigen. Science 1995; 268: 1476-1480.
29. Pierce RA, Field ED, Mutis T, Golovina TN, Von Kap-Herr C, Wilke M et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol 2001; 167: 3223-3230. (Pubitemid 32852562)
30. Torikai H, Akatsuka Y, Miyauchi H, Terakura S, Onizuka M, Tsujimura K et al. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. Bone Marrow Transplant 2007; 40: 165-174. (Pubitemid 47046215)
31. Mommaas B, Kamp J, Drijfhout JW, Beekman N, Ossendorp F, Van Veelen P et al. Identification of a novel HLA-B60-restricted Tcell epitope of the minor histocompat-ibility antigen HA-1 locus. J Immunol 2002; 169: 3131-3136. (Pubitemid 35013158)
32. Dolstra H, Fredrix H, Preijers F, Goulmy E, Figdor CG, deWitte TM et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997;158:560-565. (Pubitemid 127492630)
33. Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensink E et al. A human minor histocompatibilityantigen specific for B cell acute lymphoblastic leukemia. JExp Med 1999; 189: 301-308. (Pubitemid 29063251)
34. Dolstra H, de Rijke B, Fredrix H, Balas A, Maas F, Scherpen F et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 bycytotoxic T lymphocytes. Eur J Immunol 2002; 32: 2748-2758. (Pubitemid 35238166)
35. Akatsuka Y, Nishida T, Kondo E, Miyazaki M, Taji H, Iida H et al. Identification of a polymorphic gene, BCL2A1, encodingtwo novel hematopoietic lineage-specific minor histocompatibilityantigens. J Exp Med 2003; 197: 1489-1500. (Pubitemid 36682546)
36. Kawase T, Nannya Y, Torikai H, Yamamoto G, Onizuka M, Morishima S et al. Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. Blood 2008; 111: 3286-3294.
37. Warren EH, Vigneron NJ, Gavin MA, Coulie PG, Stroobant V, Dalet A et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006; 313: 1444-1447. (Pubitemid 44360274)
38. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, Woestenenk R et al. Aframeshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115:3506-3516. (Pubitemid 43121838)
39. Overes IM, de Rijke B, van Horssen-Zoetbrood A, Fredrix H, de Graaf AO, Jansen JH et al. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxicT-cell-mediated lysis. Br J Haematol 2008; 141: 799-807. (Pubitemid 351724862)
40. Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG et al. Myeloid leukemic progenitor cells can bespecificallytargeted by minor histocompatibility antigen LRH-1-reactivecytotoxicTcells. Blood 2009; 113: 2312-2323.
41. Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, Tsujimura A et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 2007; 110: 1055-1063. (Pubitemid 47267448)
42. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells withoutcausinggraft-versus-hostdisease. Nat Med 2001; 7: 789-794. (Pubitemid 32691632)
43. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 1983; 302: 159-161. (Pubitemid 13160997)
44. Irle C, Beatty PG, Mickelson E, Thomas ED, Hansen JA. Alloreactive Tcellresponses between HLA-identical siblings. Detection of anti-minor histocompatibility T cell clones induced in vivo. Transplantation 1985; 40: 329-333. (Pubitemid 15023197)
45. Irle C, Chapuis B, Jeannet M, Kaestli M, Montandon N, Speck B. Detection of anti-non-MHC-directed T cell reactivity following in vivo priming after HLA-identical marrow transplantation and following in vitro priming in limiting dilution cultures. Transplant Proc 1987; 19: 2674-2677.
46. Voogt PJ, Goulmy E, Veenhof WF, Hamilton M, Fibbe WE, Van Rood JJ et al. Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med 1988; 168: 2337-2347. (Pubitemid 19020909)
47. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998; 91: 2197-2207. (Pubitemid 28185527)
48. Falkenburg JH, Goselink HM, van der Harst D, van Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27-33.
49. van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060-1066. (Pubitemid 24058556)
50. + minor histocompat-ibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 8639-8644. (Pubitemid 29354844)
51. Reinsmoen NL, Kersey JH, Bach FH. Detection of HLA restricted anti-minor histo-compatibilityantigen(s) reactive cells from skin GVHD lesions. Hum Immunol 1984; 11: 249-257. (Pubitemid 15186354)
52. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissuedistribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788-1794.
53. Niederwieser D, Grassegger A, Aubock J, Herold M, Nachbaur D, Rosenmayr A et al. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 1993; 81: 2200-2208. (Pubitemid 23106739)
54. + Tcells. Blood 2010; 115: 4923-4933.
55. Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietictargets in antitumor immunity. Blood 2009; 114: 3684-3692.
56. + CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med 2008; 205: 2863-2872.
57. Kircher B, Stevanovic S, Urbanek M, Mitterschiffthaler A, Rammensee HG, Grunewald K et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002; 117: 935-939. (Pubitemid 34639258)
58. Kircher B, Wolf M, Stevanovic S, Rammensee HG, Grubeck-Loebenstein B, Gastl G et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. J Immunother 2004; 27: 156-160. (Pubitemid 38282735)
59. Jedema I, van derWerff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103: 2677-2682. (Pubitemid 38393024)
60. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific Tcells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747. (Pubitemid 36297569)
61. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specificTcells. Leukemia 2004; 18: 798-808. (Pubitemid 38500199)
62. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285. (Pubitemid 26033083)
63. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histo-compatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999; 5: 839-842. (Pubitemid 29318622)
64. Lin MT, Gooley T, Hansen JA, Tseng LH, Martin EG, Singleton K et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 3172-3173.
65. Wilke M, Dolstra H, Maas F, Pool J, Brouwer R, Falkenburg JH et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematolo-gical malignancies. Hematol J2003; 4: 315-320. (Pubitemid 37259348)
66. Fujii N, Hiraki A, Ikeda K, Ohmura Y, Nozaki I, Shinagawa K et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation 2002; 73: 1137-1141. (Pubitemid 34415449)
67. Torikai H, Akatsuka Y, Yatabe Y, Morishima Y, Kodera Y, Kuzushima K et al. Aberrant expression of BCL2A1-restricted minor histocompatibilityantigens in melanoma cells: application for allogeneic transplantation. Int J Hematol 2008; 87: 467-473.
68. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410-414. (Pubitemid 34407038)
69. Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T et al. Abnormalexpression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 2003; 120: 434-441. (Pubitemid 36241499)
70. Nishida T, Akatsuka Y, Morishima Y, Hamajima N, Tsujimura K, Kuzushima K et al. Clinical relevance of a newly identified HLA-A24-restricted minor histo-compatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrowtransplant. Br J Haematol 2004; 124: 629-635. (Pubitemid 38297096)
71. Spierings E, Hendriks M, Absi L, Canossi A, Chhaya S, Crowley J et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differ-ences among populations. PLoS Genet 2007; 3: e103.
72. Spaapen RM, de Kort RA, van den Oudenalder K, van Elk M, Bloem AC, Lokhorst HM et al. Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis. Clin Cancer Res 2009; 15: 7137-7143.
73. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999; 284: 1351-1354. (Pubitemid 29289659)
74. van de Corput L, Chaux P, van der Meijden ED, De Plaen E, Frederik Falkenburg JH, van der Bruggen P. A novel approach to identify antigens recognized by CD4Tcells using complement-opsonized bacteria expressing a cDNA library. Leukemia 2005; 19: 279-285. (Pubitemid 40220594)
75. Griffioen M, van der Meijden ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SA et al. Identification of phosphatidylinositol 4-kinasetype II beta as HLAclass II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci USA 2008; 105: 3837-3842. (Pubitemid 351723486)
76. Shrimpton RE, Butler M, Morel AS, Eren E, HueSS, Ritter MA. CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self. Mol Immunol 2009; 46: 1229-1239.
77. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann NYAcad Sci 2009; 1174: 6-17.
78. Rouse RV, Parham P, Grumet FC, Weissman IL. Expression of HLAantigens by human thymic epithelial cells. Hum Immunol 1982; 5: 21-34. (Pubitemid 13130673)
79. Ofran Y, Kim HT, Brusic V, Blake L, Mandrell M, Wu CJ et al. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibilityepitopes. Clin Cancer Res 2010; 16: 1642-1651.
80. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans bytheadoptivetransfer of Tcell clones. Science 1992; 257: 238-241.
81. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution ofcellular immunityagainst cytomegalovirus in recipientsofallogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
82. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunityagainst Epstein-Barrvirus infection byadoptivetransferofgene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555. (Pubitemid 26150682)
83. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166. (Pubitemid 44527351)
84. Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific Tcell immunity. Curr Opin Immunol 2009; 21: 224-232.
85. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854. (Pubitemid 35231542)
86. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of trans-ferred Tcells. Proc Natl Acad Sci USA 2002; 99: 16168-16173. (Pubitemid 35462767)
87. + Tcells against NY-ESO-1. N Engl J Med 2008; 358: 2698-2703. (Pubitemid 351860862)
88. + Hodgkin'sdisease. J Exp Med 2004; 200: 1623-1633. (Pubitemid 40094186)
89. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphopro-liferative disease in transplant recipients. Blood 2010; 115: 925-935.
90. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117: 1204-1212. (Pubitemid 46718405)
91. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
92. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematol Am Soc Hematol Educ Program 2009, 675-681.
93. Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide genetherapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther 2010; 21: 241-250.
94. Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115: 3869-3878.
95. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-7130. (Pubitemid 39628146)
96. Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999; 13: 166-174. (Pubitemid 29092648)
97. Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res 1999; 18: 485-492. (Pubitemid 30114737)
98. Mutis T, Ghoreschi K, Schrama E, Kamp J, Heemskerk M, Falkenburg JH et al. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. Biol Blood Marrow Transplant 2002; 8: 412-419.
99. + T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells. J Immunother 2009; 32: 539-551.
100. +Tcell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells. Transplantation 2001;71: 1449-1455. (Pubitemid 32507120)
101. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000; 74: 8207-8212. (Pubitemid 30641669)
102. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-970. (Pubitemid 32976170)
103. Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003; 102: 3530-3540. (Pubitemid 37409367)
104. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targetsnormaltissuesexpressingcognateantigen. Blood 2009; 114: 535-546.
105. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129. (Pubitemid 44547756)
106. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004; 199: 885-894. (Pubitemid 38481080)
107. van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JH, Heemskerk MH. Alphabeta T-cell receptor engineered gammadelta T cells mediate effectiveantileukemic reactivity. Cancer Res 2006; 66: 3331-3337.
108. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van derVeken LT, Hoogeboom M, Kester MG et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109: 235-243. (Pubitemid 46053064)
109. Griffioen M, van Egmond HM, Barnby-Porritt H, van der Hoorn MA, Hagedoorn RS, Kester MG et al. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica 2008; 93: 1535-1543.
110. Heemskerk MH, Griffioen M, Falkenburg JH. T-cell receptor gene transfer for treat-ment of leukemia. Cytotherapy 2008; 10: 108-115.
111. van Loenen MM, Hagedoorn RS, Kester MG, Hoogeboom M, Willemze R, Falkenburg JH et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res 2009; 69: 2034-2041.
112. van Loenen MM, de Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R et al. Mixed Tcell receptor dimers harbor potentially harmful neoreactivity Proc Natl Acad Sci USA 2010; 107: 10972-10977.
113. Bendle GM, Linnemann C, Hooijkaas AI, Bies L, deWitte MA, Jorritsma A et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010; 16: 565-570; 1pfollowing 70.
114. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-2338. (Pubitemid 46425872)
115. Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 2010; 184: 6232-6241.
116. Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 2010; 184: 6223-6231.
117. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ et al. Codon modification of Tcell receptors allows enhanced functional expression in transgenic humanTcells. Clin Immunol 2006; 119: 135-145.
118. Genovese P, Provasi E, Magnani Z, Lombardo A, Muniz Pello O, Kuball J et al. Editing central memory T lymphocyte specificity for safe and effective adoptive immunother-apy of leukemia. Proceedings of the 101st Annual Meeting of the American Associa-tion forCancer Research; 17-21 April 2010; Washington, DC AACR: Philadelphia, PA, 2010, Abstract nr 2937.
119. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specificsilencingofendogenousTCR. Cancer Res 2009; 69: 9003-9011.
120. van der Veken LT, Coccoris M, Swart E, Falkenburg JH, Schumacher TN, Heemskerk MH. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol 2009; 182: 164-170.
121. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675. (Pubitemid 37328821)
122. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357. (Pubitemid 46218728)
123. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C et al. Eradication of systemic B-cell tumors bygeneticallytargeted human T lymphocytes co-stimulated byCD80and interleukin-15. Nat Med 2003; 9: 279-286. (Pubitemid 36362782)
124. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J et al. Engineering CD19-specific T lymphocyteswith interleukin-15 and a suicidegene to
125. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-2802. (Pubitemid 350006931)
126. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763. (Pubitemid 38680440)
127. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R et al. Lineage relationship and protective immunity of memory CD8T cell subsets. Nat Immunol 2003; 4:225-234. (Pubitemid 36322131)
128. + Tcells derived from central memorycells establishes persistent Tcell memory in primates. J Clin Invest 2008; 118: 294-305.
129. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102: 9571-9576. (Pubitemid 40981722)
130. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009; 106: 17469-17474.
131. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl JMed 2003; 348: 255-256. (Pubitemid 36077924)
132. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724. (Pubitemid 27421983)
133. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-223. (Pubitemid 26057556)
134. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptivelytransferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294-2302. (Pubitemid 43345547)
135. Berger C, Blau CA, Huang ML, Iuliucci JD, Dalgarno DC, Gaschet J et al. Pharma-cologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004; 103: 1261-1269. (Pubitemid 38168636)
136. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247-4254. (Pubitemid 40720769)
137. Griffioen M, van Egmond EH, Kester MG, Willemze R, Falkenburg JH, Heemskerk MH. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 2009; 94: 1316-1320.
138. Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodys-plasticsyndrome(MDS)orMDSwithmyelofibrosis. Int J Hematol 2003; 78: 56-61. (Pubitemid 36899903)
139. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890. (Pubitemid 39298502)
140. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patientswith myeloid malignancies. Blood 2008; 111: 236-242.
141. Van Tendeloo VF, Van deVelde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of completeand molecular remissions in acute myeloid leukemia byWilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824-13829.
142. Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol 2008; 21: 391-404.
143. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F et al. RHAMM-R3 peptidevaccination in patientswith acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111: 1357-1365. (Pubitemid 351213422)
144. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Gotz M, Funk I et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010; 95:1191-1197.
145. + T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 2010; 24: 798-805.
146. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781-1787. (Pubitemid 30120843)
147. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-1042. (Pubitemid 38129569)
148. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observa-tional trial. Lancet 2005; 365: 657-662. (Pubitemid 40260886)
149. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007; 21: 2287-2295. (Pubitemid 350011701)
150. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T et al. Apilotvaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patientswith minimal disease. Leukemia 2008; 22: 1613-1616.
151. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009; 115: 3924-3934.
152. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L et al. Restoration of immunity in lymphopenic individualswith cancer by vaccination and adoptiveT-cell transfer. Nat Med 2005; 11: 1230-1237. (Pubitemid 43093671)
153. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005; 36: 315-323. (Pubitemid 41195164)
154. Verdijk RM, Kloosterman A, Pool J, van de Keur M, Naipal AM, van Halteren AG et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 2004; 103: 1961-1964. (Pubitemid 38268999)
155. Mommaas B, Stegehuis-Kamp JA, van Halteren AG, Kester M, Enczmann J, Wernet P et al. Cord blood comprises antigen-experienced Tcells specific for maternal minor histocompatibility antigen HA-1. Blood 2005; 105: 1823-1827. (Pubitemid 40223709)